Thanks, joining Ryan, to and thank everyone call the you today.
continued XXXX, of As AVISE record record we of appreciate of always, CTD care the total health we lupus quarter your our for ordering Exagen. of adopters achieved flagship test. support a and third and X,XXX providers In a XXX AVISE
AVISE QX which tests for delivered. XX,XXX was million, $XX.X CTD included Our revenue
sector from was due decline As care sequential experienced, volume variant, our has testing impacted primary patient Delta volume the seasonality. summer referrals and a in specialists by to patient
diagnosing the that a in available We members. X.X to to autoimmune to as focused are IHP, with providers number the further plan retention a we is payers speaks to status. As historically their now in the slow new clinically health million remain approximately accelerate and and process of country, frustrating AVISE among referred engaged available across high our to like AVISE AVISE in-network adopting to reflects is and Once health not-for-profit lupus and value Medicare/Medicaid meaningful million in-network We Plan, have the agreement this at This now in make network membership population signed rheumatologists, using or to recently in coverage Health their XX% a and Empire on disorders. IHP benefit Inland reminder, an largest very specialists, most recognize care an diseases. testing our customers of ordering XX.X testing high believe diagnostic physicians. autoimmune the saw access again, retention AVISE in care the also higher providers in-network care of continued the increase patients Exagen, from primary not from quarter. patients win rate rate prior was only of for expand the tests but We risk highly lives testing. significant that volumes to are for U.S.
number our ordering increasing health of care our in tests As rheumatology. service a provide illustrates, providers much-needed
treatment therapies patients for goal the how methotrexate tool in expect footprint therapy Despite dose agreement the to to past happy necessary And keep of multiple continue AVISE to Patients for for over few to in-network the to RA. the the or a entered optimize MTX MTX range. pilot to leverage MTX announce therapy. price. AVISE that medicine helps the supply of remains advent they a We we to I'm cornerstone a to of our partnership rheumatologists benefiting regards a CVS grow, is making Aetna. coverage between selling pilot have and average RA our appropriate methotrexate, increasing the of rheumatoid and personalized metabolize also use differ arthritis, critical difficult. AVISE biologic as selection methotrexate in The the new therapeutic decades, into
we the this the development I'd future While exclusive AVISE now switch to research like also remaining property the to intellectual royalty. we own initiatives. financial by our rights position over our quarter, improved powering and to MTX, buying out
Hilltop clinical XX are the needs the rheumatology significant our research, market total past expand pipeline of tests According the addressable dramatically R&D, use our to raised advanced decade, have Own and unmet and develop across in focused multiomics we novel our market developed Over proceeds for including XXXX, multiple on tests. as we our in rheumatology successfully products strategy. to deliver remains in Through commercialized in of indications. investments there and part QX
should approximately more to antibody clinical had research of that AVISE to panel lupus abstracts AVISE utility yesterday. very actionable this significantly tested record with the than testing the quality traditional be patients traditional will The clinically very our American concluded Conference, demonstrates abstract traditional development with ANA of of to X test. was ANA traditional as study paper, antinuclear positive bound world-class be by a the with utility the and clinical versus believe College on XXXx diagnosis antibody strengthen of XX,XXX as which patients The position testing utility that lupus our meaningful. the key testing than studies strategy cohort our cell efficacy was treatment proud the I'd an continues and and product in payers larger Rheumatology's by customers we Premier patients the patients complement organization highlight testing activation for our these assay believe approach. this to Annual diagnosed the one XX,XXX Xx health portfolio. approach. inform abstract, of be abstracts leveraging on testing team clinical In shown with will it more our are its medication database utility accepted the study likely likely start to In approximately care electronic Xx positive more of incremental future tested our for than than SLE, antinuclear consisting further We further testing were the and testing. like reinforce contributions prior multianalyte and the a AVISE to lupus We of are abstracts with described titled, lupus more further of the
announced and reliable massive lack enrolled you initiatives. hard historically representing future. of estimated at study, XX improve the has more due a early patient the that fully fibromyalgia cost the can also been savings thrombosis tell to the forward underserved to which scientific opportunity the health We we you quarter consists look to XXXX. team to and outcome regards patient diagnostic patients, last deliver the [BETTER] several details benefit system. work of our has and test, launch be approximately We for population to on test Our with is been to care million fibromyalgia sharing by In in of
to will test the voclosporin We are enhance progress how lupus SLE SLE when the address patient monitoring We with that monitoring our the lupus also lupus these additional belimumab the developing indication. on XX% monitor patients with to physician and for our in to to deadly with feel nephritis therapies. of received nephritis. Recently, and Aurinia markers SLE approximately enhancing to working approval GSK move potentially nephritis to expensive FDA regards test patient assist
is schedule Our our to important will be XXXX, molecular to that note is clinical clinical expansion further expected R&D include continues which and multiomics. XXXX. be expected in and lab to completed and and our by R&D will increase efforts QX expansion lab molecular lab completed It's on by our capabilities, multiomics QX
hire with team history has Lee continue Technology talent, to previously recent in test. Ming-Chou who our exceptional ArcherDX. Dr. scientific worked Lee, the extensive diagnostic Officer and at Chief is Ph.D, of our molecular grow developing including We
I initiatives. to Kamal, leads join our Lee are the We financial development he RA over have Dr. discuss now pleased of our the our pipeline us to call turn CFO, to results. as will
